Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Optimal treatment sequences for advanced pancreatic cancer were evaluated. FOLFIRINOX followed by gemcitabine/nab-paclitaxel showed potential benefits for poor-risk patients, warranting further trials.
Area Of Science
- Oncology
- Clinical Research
- Cancer Treatment
Background
- Optimal treatment sequencing for advanced pancreatic cancer lacks clear guidelines due to a scarcity of head-to-head trials.
- Real-world data is crucial for understanding the effectiveness of different palliative chemotherapy regimens.
Purpose Of The Study
- To compare the real-world effectiveness of three common first- to second-line sequential treatment strategies for advanced pancreatic cancer.
- To assess overall survival (OS) and time to deterioration (TTD) of health-related quality of life (HRQoL) based on treatment sequence and patient risk stratification.
Main Methods
- Analysis of 1551 advanced pancreatic cancer patients from the Tumour Registry Pancreatic Cancer cohort.
- Utilized marginal structural modeling to emulate a randomized trial, comparing FOLFIRINOX→GEMNAB, GEMNAB→FOLFOX/OFF, and GEMNAB→NALIRI+5-fluorouracil sequences.
- Outcomes stratified by prognostic risk using the Pancreatic Cancer Score.
Main Results
- Median OS and TTD of HRQoL were largely comparable across the three sequences for the overall cohort.
- Poor-risk patients receiving GEMNAB→FOLFOX/OFF or GEMNAB→NALIRI+5-fluorouracil showed worse OS and TTD compared to FOLFIRINOX→GEMNAB.
- Hazard ratios indicated significantly worse outcomes for poor-risk patients in the GEMNAB→FOLFOX/OFF arm (OS: 2.09, TTD: 1.97) and the GEMNAB→NALIRI+5-fluorouracil arm (TTD: 2.62).
Conclusions
- Real-world effectiveness of the evaluated sequential treatments for advanced pancreatic cancer was generally comparable.
- The FOLFIRINOX→GEMNAB sequence may offer improved clinical and patient-reported outcomes for poor-risk individuals.
- Further randomized trials are essential to establish definitive optimal sequential treatment strategies in advanced pancreatic cancer.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.